Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ALFACYTE LIMITED logo — Pioneering an innovative therapy for the oral treatment of p...

ALFACYTE LIMITED

Pioneering an innovative therapy for the oral treatment of peanut allergy with a dual-cytokine, immunoregulation approach.

Founded 2012 1 employees Venture round Total: $250.00K Biotechnology, Health Care +1

General Information

Company Name ALFACYTE LIMITED
Founded Year 2012
Employees 1
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with ALFACYTE LIMITED. To contact ALFACYTE LIMITED, visit alfacyte.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ALFACYTE LIMITED compare?

A PDF of ALFACYTE LIMITED and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ALFACYTE LIMITED soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ALFACYTE LIMITED

Alfacyte Limited, founded in 2012, is a biotechnology startup pioneering an innovative therapy for the oral treatment of peanut allergy with a dual-cytokine, immunoregulation approach. The company's slogan reflects its dedication to leveraging the immunological benefits of two specific candidate cytokines with similar activities to adjuvants in the development of an innovative formulation for the oral treatment of food allergies. Their combination therapy aims to treat peanut allergy effectively through oral administration, showcasing their commitment to addressing a critical health concern. In January 2017, the company secured a £250.00K Venture Round investment from EOS Technology Investment Syndicate and Scottish Investment Bank, signifying confidence in their innovative approach and potential for impact within the Health Care industry.

Business keywords: Peanut Allergy, Therapy, Immunoregulation, Cytokines, Adjuvants, Oral Treatment, Food Allergies, Formulation, Immunological, Combination Therapy, Innovative, Biotech, Immunotherapy, Start-up, Medical Innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round £250.00K 2
EOS Technology Investment Syndicate
EOS Technology Investment Syndicate, Scottish Investment Bank
04 Jan 2017

ALFACYTE LIMITED Alternatives & Competitors

View All Alternatives
ALFACYTE LIMITED vs
DBV Technologies
DBV Technologies France

On a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin...

Post-IPO Equity
187 employees
Biopharma, Biotechnology
ALFACYTE LIMITED vs
Intrommune Therapeutics
Intrommune Therapeutics United States

Dedicated to developing safe and effective options for peanut and other food allergies

Series B
17 employees
Biotechnology, Health Care
ALFACYTE LIMITED vs
Aspire Allergy & Sinus
Aspire Allergy & Sinus United States

Simple Relief. Better Life.

Private Equity
197 employees
Health Care, Health and Wellness
Compare ALFACYTE LIMITED vs Aspire Allergy & Sinus
View all alternatives

FAQ About ALFACYTE LIMITED

Pioneering an innovative therapy for the oral treatment of peanut allergy with a dual-cytokine, immunoregulation approach.
ALFACYTE LIMITED was founded in 2012.
ALFACYTE LIMITED operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Peanut Allergy, Therapy, Immunoregulation and Cytokines.
ALFACYTE LIMITED has approximately 1 employees.
ALFACYTE LIMITED has completed 1 funding round, raising a total of $250.00K. The latest funding stage is Venture round.
Top alternatives and competitors to ALFACYTE LIMITED include DBV Technologies, Intrommune Therapeutics, Aspire Allergy & Sinus, Aravax, Boostimmune. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ALFACYTE LIMITED and DBV Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ALFACYTE LIMITED, https://bouncewatch.com/company/alfacyte-limited, updated 12 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes